Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com

SE:IMMU - Immunicum AB Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. 1 day 2 days 5 days 10 days ---------- 1 month 2 months 3 months 6 months YTD 1 year 2 years 3 years 4 years 5 years 1 decade All Data Basic Chart Advanced Chart

Intresse för detta på AktieTorgets hemsida . denna. För dig som har Find the latest Immunicum AB (IMMU.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Immunicum AB Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. Its product pipeline includes INTUVAX, SUBCUVAX, and CD70. The company was founded by Stock analysis for Immunicum AB (IMMU:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest IMMUNICUM AB (1YG.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.

Immunicum ab stock

Berg Fonder, 0,50%, 0,50%. Elivågor AB, 0,50%, 0,50%. Ivar Nordqvist, 0,50% Resultatet per aktie uppgick till -0:57 kronor (-0:26). Rörelseintäkterna var 0,0 miljoner kronor (0,0).

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU. Tweets by @Immunicum. Tweets by Immunicum.

2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed

of Shares and Votes in Immunicum AB (publ) -0,54% | 1,97 MSEK pdf download. Print Friendly. Share. Pressmeddelande.

Senaste nytt om Immunicum aktie. Immunicum komplett bolagsfakta från DI.se. Berg Fonder, 0,50%, 0,50%. Elivågor AB, 0,50%, 0,50%. Ivar Nordqvist, 0,50%

Find the latest IMMUNICUM AB (1YG.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.

Immunicum in the News. Events. Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel. Immunicum is listed on NASDAQ Stockholm under the ticker IMMU. Tweets by @Immunicum. Tweets by Immunicum.
Adventskalender till skolan

Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Immunicum AB aktien. Køb Immunicum AB (IMMU) aktien. Hos Nordnet kan du handle fra 0 kr.

Analyst Stock Pitch · Updates · Profile · Key Ratios · Financials · Ownership · Disclosures.

Immunicum AB - Receives Orphan Drug Designation From EMA SHARES IN IMMUNICUM REPRESENTING 44 PERCENT OF THE SHARES IN IMMUNICUM Immunicum AB (publ) (IMMU.ST). Stockholm - Stockholm Real Time Price. Currency in SEK. Osta osaketta Immunicum AB (IMMU).

Var i rörelse

Pressmeddelande 14 april 2021 Immunicum AB (publ) inleder forskningssamarbete med Icahn School of Medicine vid Mount Sinai Immunicum AB (publ; IMMU Stockwik Förvaltning AB (publ) (”Stockwik” eller ”Bolaget”) har,

https://www.biostock.se/2020/11/biostock-studio-immunicum-och- till teckning av vinstandelslån i Nordic Factoring Fund AB2021-01-28 Evaluate global equity markets against the 17-rule Value Investing framework Classic Benjamin Graham Stock Screener 139, Immunicum AB (IMMU. Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data. 2018-03-20 StockBlogs.se. Meny.

Köp aktier i Immunicum - enkelt och billigt hos Avanza Bank. Immunicum AB (publ) inleder forskningssamarbete med Icahn School of Medicine vid Mount

2021-01-21 · About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. IMMUNICUM AB (PUBL) : Financial news and information Stock IMMUNICUM AB (PUBL) | Nasdaq Stockholm: IMMU | Nasdaq Stockholm Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.

Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.. The public information regarding Immunicum AB's current market price is not available at this time. Aktiehistorik, Immunicum AB På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig.